1156 related articles for article (PubMed ID: 30951251)
41. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study.
Ibfelt EH; Jacobsen RK; Kopp TI; Cordtz RL; Jakobsen AS; Seersholm N; Shaker SB; Dreyer L
Rheumatology (Oxford); 2021 Jan; 60(1):346-352. PubMed ID: 32780828
[TBL] [Abstract][Full Text] [Related]
42. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.
Zhang Y; Li H; Wu N; Dong X; Zheng Y
Clin Rheumatol; 2017 Apr; 36(4):817-823. PubMed ID: 28191607
[TBL] [Abstract][Full Text] [Related]
43. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease.
Tyker A; Ventura IB; Lee CT; Strykowski R; Garcia N; Guzy R; Jablonski R; Vij R; Strek ME; Chung JH; Adegunsoye A
Sci Rep; 2021 Nov; 11(1):22821. PubMed ID: 34819525
[TBL] [Abstract][Full Text] [Related]
44. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA.
Shidara K; Hoshi D; Inoue E; Yamada T; Nakajima A; Taniguchi A; Hara M; Momohara S; Kamatani N; Yamanaka H
Mod Rheumatol; 2010 Jun; 20(3):280-6. PubMed ID: 20217173
[TBL] [Abstract][Full Text] [Related]
45. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease.
Castellanos-Moreira R; Rodríguez-García SC; Gomara MJ; Ruiz-Esquide V; Cuervo A; Casafont-Solé I; Ramírez J; Holgado S; Gómez-Puerta JA; Cañete JD; Haro I; Sanmarti R
Ann Rheum Dis; 2020 May; 79(5):587-594. PubMed ID: 32156708
[TBL] [Abstract][Full Text] [Related]
46. Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.
Samhouri BF; Vassallo R; Achenbach SJ; Kronzer VL; Davis JM; Myasoedova E; Crowson CS
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2042-2049. PubMed ID: 34995017
[TBL] [Abstract][Full Text] [Related]
47. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Qiu M; Jiang J; Nian X; Wang Y; Yu P; Song J; Zou S
Respir Res; 2021 Oct; 22(1):264. PubMed ID: 34635095
[TBL] [Abstract][Full Text] [Related]
48. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease.
Brooks R; Baker JF; Yang Y; Roul P; Kerr GS; Reimold AM; Kunkel G; Wysham KD; Singh N; Lazaro D; Monach PA; Poole JA; Ascherman DP; Mikuls TR; England BR
Rheumatology (Oxford); 2022 Nov; 61(12):4667-4677. PubMed ID: 35377443
[TBL] [Abstract][Full Text] [Related]
49. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities.
Salaffi F; Carotti M; Di Carlo M; Tardella M; Giovagnoni A
Medicine (Baltimore); 2019 Sep; 98(38):e17088. PubMed ID: 31567944
[TBL] [Abstract][Full Text] [Related]
50. Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Kim JW; Chung SW; Pyo JY; Chang SH; Kim MU; Park CH; Lee JS; Lee JS; Ha YJ; Kang EH; Lee YA; Park YB; Lee EY; Choe JY
Rheumatology (Oxford); 2023 Jul; 62(7):2377-2385. PubMed ID: 36394143
[TBL] [Abstract][Full Text] [Related]
51. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
[TBL] [Abstract][Full Text] [Related]
52. Factors associated with interstitial lung disease in patients with rheumatoid arthritis: A systematic review and meta-analysis.
Zhang M; Yin J; Zhang X
PLoS One; 2023; 18(6):e0286191. PubMed ID: 37352174
[TBL] [Abstract][Full Text] [Related]
53. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.
Fu Q; Wang L; Li L; Li Y; Liu R; Zheng Y
Clin Rheumatol; 2019 Apr; 38(4):1109-1116. PubMed ID: 30535993
[TBL] [Abstract][Full Text] [Related]
54. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
55. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort.
Koduri G; Norton S; Young A; Cox N; Davies P; Devlin J; Dixey J; Gough A; Prouse P; Winfield J; Williams P;
Rheumatology (Oxford); 2010 Aug; 49(8):1483-9. PubMed ID: 20223814
[TBL] [Abstract][Full Text] [Related]
56. Rheumatoid arthritis disease activity significantly impacts on the severity of interstitial lung disease.
Ito Y; Ichikawa Y; Murashima S; Sakuma H; Nakajima A
Arthritis Res Ther; 2024 May; 26(1):95. PubMed ID: 38704556
[TBL] [Abstract][Full Text] [Related]
57. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease.
Wolfe F; Caplan L; Michaud K
Scand J Rheumatol; 2007; 36(3):172-8. PubMed ID: 17657669
[TBL] [Abstract][Full Text] [Related]
58. Rheumatoid arthritis-associated interstitial lung disease: lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity.
Pérez-Dórame R; Mejía M; Mateos-Toledo H; Rojas-Serrano J
Reumatol Clin; 2015; 11(1):12-6. PubMed ID: 24913966
[TBL] [Abstract][Full Text] [Related]
59. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry.
Vadillo C; Nieto MA; Romero-Bueno F; Leon L; Sanchez-Pernaute O; Rodriguez-Nieto MJ; Freites D; Jover JA; Álvarez-Sala JL; Abasolo L
Rheumatology (Oxford); 2020 Aug; 59(8):2099-2108. PubMed ID: 31990338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
